Keyphrases
Prostate Cancer
100%
Combination Immunotherapy
100%
Metastatic Castration-resistant Prostate Cancer (mCRPC)
100%
Checkpoint Inhibitors
66%
Immune Response
33%
Clinical Trials
33%
Targeted Therapy
33%
Tumor Subtype
33%
Malignancy
33%
Immunosuppressive Agents
33%
Chimeric Antigen Receptor T Cells (CAR-T)
33%
Cancer Clinical Trials
33%
Clinical Trial Development
33%
Radiotherapy
33%
Tyrosine Kinase Inhibitor
33%
Cellular Immunity
33%
Radical Prostatectomy
33%
Advanced Prostate Cancer
33%
Immunomodulatory
33%
Immunosuppressive Microenvironment
33%
Prostate-specific Antigen Recurrence
33%
Ongoing Trials
33%
PARP Inhibitor (PARPi)
33%
Androgen Deprivation Therapy
33%
Prostate-specific Antigen Doubling Time
33%
Taxane-based Chemotherapy
33%
Medicine and Dentistry
Prostate Cancer
100%
Immunotherapy
100%
Castration Resistant Prostate Cancer
100%
Recurrent Disease
75%
Clinical Trial
50%
Prostate Specific Antigen
50%
Neoplasm
25%
Cancer
25%
Immune Response
25%
Targeted Therapy
25%
Immunosuppressive Drug
25%
Prostatectomy
25%
Tumor Microenvironment
25%
Cellular Immunity
25%
Chimeric Antigen Receptor T-Cell
25%
Tyrosine-Kinase Inhibitor
25%
PARP Inhibitor
25%
Androgen Deprivation Therapy
25%
Radiation Therapy
25%
Pharmacology, Toxicology and Pharmaceutical Science
Prostate Cancer
100%
Immunotherapy
100%
Castration Resistant Prostate Cancer
100%
Recurrent Disease
75%
Clinical Trial
50%
Prostate Specific Antigen
50%
Neoplasm
25%
Chemotherapy
25%
Immunosuppressive Agent
25%
Tumor Microenvironment
25%
Androgen
25%
Chimeric Antigen Receptor
25%
Protein Tyrosine Kinase Inhibitor
25%
Nicotinamide Adenine Dinucleotide Adenosine Diphosphate Ribosyltransferase Inhibitor
25%
Taxane
25%